- Expansion adds a new facility to Lonza’s Drug Product Services (DPS) footprint, supporting clinical and commercial projects through additional quality control (QC) and bioanalytics capacity
- Additional capacity supports growing demand in the clinical and commercial manufacture of biologic drug products (DP)
Basel, Switzerland, 15 October 2024 – Lonza, a global manufacturing partner to the pharmaceutical, biotech and nutraceutical markets, today announced it has enhanced its drug product services offering by adding a new facility for quality control and bioanalytics at its DPS site in Basel (CH) to support Lonza’s global DP capacity increase. It will enable Lonza to accelerate product delivery, which is crucial for enabling its customers to progress through clinical development and commercialization.
The planned expansion includes 6000m2 of state-of-the-art laboratories and office space to support market demand for early and late-stage clinical and commercial DP QC. The new facility allows DPS to double its capacity for the development and testing of parenteral dosage forms and strengthens existing DP capabilities offered from the Stücki Technology Park in Basel (CH).
Peter Droc, Head of Drug Product Services, Lonza, commented: “Expanding Lonza’s drug product capacity is a key enabler of our wider Biologics strategy to offer drug developers a seamless solution across modalities, from early development to drug substance and drug product manufacture. With the demand for drug product manufacturing continuing to increase, this new bioanalytics and QC facility will enable us to provide our customers with crucial manufacturing services for the delivery of life-saving medicines.”
Additional Information
For more information about Lonza's drug product manufacturing capabilities, please visit: https://pharma.lonza.com/offerings/parenteral-drug-product